A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms NABNEC
- 20 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2018.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 18 May 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.